{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T05:08:46Z","timestamp":1773464926976,"version":"3.50.1"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T00:00:00Z","timestamp":1764892800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T00:00:00Z","timestamp":1767657600000},"content-version":"vor","delay-in-days":32,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Precis. Onc."],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Despite improvements in the molecular profiling of pancreatic neuroendocrine tumors (PanNETs), predicting their clinical behavior and response to specific therapies remains challenging. We sought to elucidate the molecular basis underlying the broad phenotypic variations in these neoplasms through a genetic characterization of primary and metastatic PanNETs. Our findings revealed an enrichment of\n                    <jats:italic>CDKN2A<\/jats:italic>\n                    homozygous deletions and\n                    <jats:italic>TSC2<\/jats:italic>\n                    somatic mutations in metastatic PanNETs when compared to non-metastatic lesions. Tumor evolution analysis further revealed the acquisition of such genetic alterations as late events in the progression of these neoplasms, conferring poor survival outcomes to the affected patients. Biallelic loss of DNA damage repair genes,\n                    <jats:italic>ATRX<\/jats:italic>\n                    and\/or\n                    <jats:italic>DAXX<\/jats:italic>\n                    , was associated with a high fraction of the genome altered in PanNETs, with pathogenic alterations affecting those genes also being associated with a homologous recombination deficiency signature. These findings highlight molecular mechanisms driving PanNET progression and underscore the need for further molecular characterization and tumor evolution studies to evaluate targeted therapies for such a challenging disease.\n                  <\/jats:p>","DOI":"10.1038\/s41698-025-01210-2","type":"journal-article","created":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T16:54:15Z","timestamp":1764953655000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["CDKN2A homozygous deletions and TSC2 somatic mutations in metastatic pancreatic neuroendocrine tumors"],"prefix":"10.1038","volume":"10","author":[{"given":"Tito Teles","family":"Jesus","sequence":"first","affiliation":[]},{"given":"Lorenzo","family":"Ferrando","sequence":"additional","affiliation":[]},{"given":"Lia","family":"Rodrigues","sequence":"additional","affiliation":[]},{"given":"Rui Sousa","family":"Martins","sequence":"additional","affiliation":[]},{"given":"Lu\u00eds","family":"Cardoso","sequence":"additional","affiliation":[]},{"given":"Jos\u00e9 Manuel","family":"Lopes","sequence":"additional","affiliation":[]},{"given":"Paula","family":"Soares","sequence":"additional","affiliation":[]},{"given":"Arnaud","family":"Da Cruz Paula","sequence":"additional","affiliation":[]},{"given":"Jo\u00e3o","family":"Vinagre","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2025,12,5]]},"reference":[{"key":"1210_CR1","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1001\/jamaoncol.2017.0589","volume":"3","author":"A Dasari","year":"2017","unstructured":"Dasari, A. et al. Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States. JAMA Oncol. 3, 1335\u20131342 (2017).","journal-title":"JAMA Oncol."},{"key":"1210_CR2","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1093\/oncolo\/oyab039","volume":"27","author":"A Dasari","year":"2022","unstructured":"Dasari, A., Shen, C., Devabhaktuni, A., Nighot, R. & Sorbye, H. Survival According to Primary Tumor Location, Stage, and Treatment Patterns in Locoregional Gastroenteropancreatic High-grade Neuroendocrine Carcinomas. Oncologist 27, 299\u2013306 (2022).","journal-title":"Oncologist"},{"key":"1210_CR3","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1158\/1078-0432.CCR-16-1113","volume":"23","author":"AD Singhi","year":"2017","unstructured":"Singhi, A. D. et al. Alternative Lengthening of Telomeres and Loss of DAXX\/ATRX Expression Predicts Metastatic Disease and Poor Survival in Patients with Pancreatic Neuroendocrine Tumors. Clin. Cancer Res. 23, 600\u2013609 (2017).","journal-title":"Clin. Cancer Res."},{"key":"1210_CR4","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1097\/MPA.0000000000001535","volume":"49","author":"X Han","year":"2020","unstructured":"Han, X. et al. Aberration of ARID1A Is Associated With the Tumorigenesis and Prognosis of Sporadic Nonfunctional Pancreatic Neuroendocrine Tumors. Pancreas 49, 514\u2013523 (2020).","journal-title":"Pancreas"},{"key":"1210_CR5","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1126\/science.1200609","volume":"331","author":"Y Jiao","year":"2011","unstructured":"Jiao, Y. et al. DAXX\/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. Science 331, 1199\u2013203 (2011).","journal-title":"Science"},{"key":"1210_CR6","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1038\/nature21063","volume":"543","author":"A Scarpa","year":"2017","unstructured":"Scarpa, A. et al. Whole-genome landscape of pancreatic neuroendocrine tumours. Nature 543, 65\u201371 (2017).","journal-title":"Nature"},{"key":"1210_CR7","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms8538","volume":"6","author":"D Clynes","year":"2015","unstructured":"Clynes, D. et al. Suppression of the alternative lengthening of telomere pathway by the chromatin remodelling factor ATRX. Nat. Commun. 6, 7538 (2015).","journal-title":"Nat. Commun."},{"key":"1210_CR8","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1200\/JCO.2008.21.5988","volume":"28","author":"E Missiaglia","year":"2010","unstructured":"Missiaglia, E. et al. Pancreatic endocrine tumors: expression profiling evidences a role for AKT-mTOR pathway. J. Clin. Oncol. 28, 245\u201355 (2010).","journal-title":"J. Clin. Oncol."},{"key":"1210_CR9","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1159\/000530968","volume":"113","author":"Y Guo","year":"2023","unstructured":"Guo, Y. et al. Molecular and Functional Heterogeneity of Primary Pancreatic Neuroendocrine Tumors and Metastases. Neuroendocrinology 113, 943\u2013956 (2023).","journal-title":"Neuroendocrinology"},{"key":"1210_CR10","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/j.cell.2022.01.003","volume":"185","author":"B Nguyen","year":"2022","unstructured":"Nguyen, B. et al. Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patients. Cell 185, 563\u2013575 e11 (2022).","journal-title":"Cell"},{"key":"1210_CR11","doi-asserted-by":"publisher","first-page":"e230292","DOI":"10.1530\/ERC-23-0292","volume":"31","author":"D Cowzer","year":"2024","unstructured":"Cowzer, D. et al. Clinical utility of plasma cell-free DNA in pancreatic neuroendocrine neoplasms. Endocr. Relat. Cancer 31, e230292 (2024).","journal-title":"Endocr. Relat. Cancer"},{"key":"1210_CR12","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1038\/s41586-024-08167-5","volume":"636","author":"J Jee","year":"2024","unstructured":"Jee, J. et al. Automated real-world data integration improves cancer outcome prediction. Nature 636, 728\u2013736 (2024).","journal-title":"Nature"},{"key":"1210_CR13","unstructured":"ICGC\/TCGA Pan-cancer analysis of whole genomes consortium Pan-cancer analysis of whole genomes. Nature 578, 82\u201393 (2020)."},{"key":"1210_CR14","doi-asserted-by":"publisher","first-page":"2060","DOI":"10.1053\/j.gastro.2018.02.026","volume":"154","author":"S Roy","year":"2018","unstructured":"Roy, S. et al. Loss of Chromatin-Remodeling Proteins and\/or CDKN2A Associates With Metastasis of Pancreatic Neuroendocrine Tumors and Reduced Patient Survival Times. Gastroenterology 154, 2060\u20132063.e8 (2018).","journal-title":"Gastroenterology"},{"key":"1210_CR15","doi-asserted-by":"publisher","DOI":"10.1038\/srep13563","volume":"4","author":"B Tang","year":"2015","unstructured":"Tang, B. et al. Clinicopathological significance of CDKN2A promoter hypermethylation frequency with pancreatic cancer. Sci. Rep. 4, 13563 (2015).","journal-title":"Sci. Rep."},{"key":"1210_CR16","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1097\/01.sla.0000086659.49569.9e","volume":"238","author":"MG House","year":"2003","unstructured":"House, M. G. et al. Aberrant hypermethylation of tumor suppressor genes in pancreatic endocrine neoplams. Ann. Surg. 238, 423\u201331 (2003).","journal-title":"Ann. Surg."},{"key":"1210_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/srep39565","volume":"23","author":"D Campa","year":"2016","unstructured":"Campa, D. et al. Common germline variants within the CDKNA\/B region affect risk of pancreatic neuroendocrine tumors. Sci. Rep. 23, 39565 (2016).","journal-title":"Sci. Rep."},{"key":"1210_CR18","doi-asserted-by":"publisher","first-page":"e949","DOI":"10.1097\/SLA.0000000000003624","volume":"274","author":"J Uemura","year":"2021","unstructured":"Uemura, J. et al. Immunohistochemically Detected Expression of ATRX, TSC2, and PTEN Predicts Clinical Outcomes in Patients With Grade 1 and 2 Pancreatic Neuroendocrine Tumors. Ann. Surg. 274, e949\u2013e956 (2021).","journal-title":"Ann. Surg."},{"key":"1210_CR19","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1200\/JCO.22.01013","volume":"41","author":"PL Kunz","year":"2023","unstructured":"Kunz, P. L. et al. Randomized Study of Temozolomide or Temozolomide and Capecitabine in Patients With Advanced Pancreatic Neuroendocrine Tumors (ECOG-ACRIN E2211). J. Clin. Oncol. 41, 1359\u20131369 (2023).","journal-title":"J. Clin. Oncol."},{"key":"1210_CR20","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1053\/j.gastro.2013.10.020","volume":"146","author":"I Marinoni","year":"2014","unstructured":"Marinoni, I. et al. Loss of DAXX and ATRX are associated with chromosome instability and reduced survival of patients with pancreatic neuroendocrine tumors. Gastroenterology 146, 453\u201360 e5 (2014).","journal-title":"Gastroenterology"},{"key":"1210_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-32680-8","volume":"13","author":"N Gulve","year":"2022","unstructured":"Gulve, N. et al. DAXX-ATRX regulation of p53 chromatin binding and DNA damage response. Nat. Commun. 13, 5033 (2022).","journal-title":"Nat. Commun."},{"key":"1210_CR22","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.691557","volume":"12","author":"F Wang","year":"2021","unstructured":"Wang, F. et al. Prognostic significance of altered ATRX\/DAXX gene in pancreatic neuroendocrine tumors: a meta-analysis. Front Endocrinol. 12, 691557 (2021).","journal-title":"Front Endocrinol."},{"key":"1210_CR23","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s12022-025-09848-1","volume":"36","author":"BR Veld","year":"2025","unstructured":"Veld, B. R., Hackeng, W. M., Luchini, C., Brosens, L. A. & Dreijerink, K. M. Clinical relevance of ATRX\/DAXX gene mutations and ALT in functioning pancreatic neuroendocrine tumors. Endocr. Pathol. 36, 3 (2025).","journal-title":"Endocr. Pathol."},{"key":"1210_CR24","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.molcel.2018.05.014","volume":"71","author":"S Juhasz","year":"2018","unstructured":"Juhasz, S., Elbakry, A., Mathes, A. & Lobrich, M. ATRX Promotes DNA Repair Synthesis and Sister Chromatid Exchange during Homologous Recombination. Mol. Cell 71, 11\u201324.e7 (2018).","journal-title":"Mol. Cell"},{"key":"1210_CR25","doi-asserted-by":"publisher","first-page":"101147","DOI":"10.1016\/j.tranon.2021.101147","volume":"14","author":"J Garbarino","year":"2021","unstructured":"Garbarino, J., Eckroate, J., Sundaram, R. K., Jensen, R. B. & Bindra, R. S. Loss of ATRX confers DNA repair defects and PARP inhibitor sensitivity. Transl. Oncol. 14, 101147 (2021).","journal-title":"Transl. Oncol."},{"key":"1210_CR26","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1007\/s12020-024-03968-0","volume":"86","author":"V Maximo","year":"2024","unstructured":"Maximo, V., Melo, M., Sobrinho-Sim\u00f5es, M., Soares, P. & Da Cruz Paula, A. Genomic profiling of lymph node and distant metastases from papillary and poorly differentiated thyroid carcinomas. Endocrine 86, 505\u2013509 (2024).","journal-title":"Endocrine"},{"key":"1210_CR27","volume":"31","author":"V Maximo","year":"2024","unstructured":"Maximo, V. et al. Genomic profiling of primary and metastatic thyroid cancers. Endocr. Relat. Cancer 31, e230144 (2024).","journal-title":"Endocr. Relat. Cancer"},{"key":"1210_CR28","first-page":"PO.19.00103","volume":"3","author":"ES Smith","year":"2019","unstructured":"Smith, E. S. et al. Endometrial Cancers in BRCA1 or BRCA2 Germline Mutation Carriers: Assessment of Homologous Recombination DNA Repair Defects. JCO Precis. Oncol. 3, PO.19.00103 (2019).","journal-title":"JCO Precis. Oncol."},{"key":"1210_CR29","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1038\/nbt.2203","volume":"30","author":"SL Carter","year":"2012","unstructured":"Carter, S. L. et al. Absolute quantification of somatic DNA alterations in human cancer. Nat. Biotechnol. 30, 413\u201321 (2012).","journal-title":"Nat. Biotechnol."},{"key":"1210_CR30","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-13806-x","volume":"11","author":"SH Kim","year":"2020","unstructured":"Kim, S. H. et al. Identification of recurrent FHL2-GLI2 oncogenic fusion in sclerosing stromal tumors of the ovary. Nat. Commun. 11, 44 (2020).","journal-title":"Nat. Commun."},{"key":"1210_CR31","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1038\/ng.3781","volume":"49","author":"FP Barthel","year":"2017","unstructured":"Barthel, F. P. et al. Systematic analysis of telomere length and somatic alterations in 31 cancer types. Nat. Genet. 49, 349\u2013357 (2017).","journal-title":"Nat. Genet."},{"key":"1210_CR32","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-016-0893-4","volume":"17","author":"R Rosenthal","year":"2016","unstructured":"Rosenthal, R., McGranahan, N., Herrero, J., Taylor, B. S. & Swanton, C. DeconstructSigs: delineating mutational processes in single tumors distinguishes DNA repair deficiencies and patterns of carcinoma evolution. Genome Biol. 17, 31 (2016).","journal-title":"Genome Biol."},{"key":"1210_CR33","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.ygyno.2018.10.032","volume":"152","author":"CW Ashley","year":"2019","unstructured":"Ashley, C. W. et al. Analysis of mutational signatures in primary and metastatic endometrial cancer reveals distinct patterns of DNA repair defects and shifts during tumor progression. Gynecol. Oncol. 152, 11\u201319 (2019).","journal-title":"Gynecol. Oncol."},{"key":"1210_CR34","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms14114","volume":"8","author":"JG Reiter","year":"2017","unstructured":"Reiter, J. G. et al. Reconstructing metastatic seeding patterns of human cancers. Nat. Commun. 8, 14114 (2017).","journal-title":"Nat. Commun."},{"key":"1210_CR35","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1038\/s41379-020-00721-6","volume":"34","author":"LA Moukarzel","year":"2021","unstructured":"Moukarzel, L. A. et al. Clonal relationship and directionality of progression of synchronous endometrial and ovarian carcinomas in patients with DNA mismatch repair-deficiency associated syndromes. Mod. Pathol. 34, 994\u20131007 (2021).","journal-title":"Mod. Pathol."},{"key":"1210_CR36","doi-asserted-by":"publisher","first-page":"3682","DOI":"10.1158\/1078-0432.CCR-19-2563","volume":"26","author":"F Pareja","year":"2020","unstructured":"Pareja, F. et al. Whole-exome sequencing analysis of the progression from non-low-grade ductal carcinoma in situ to invasive ductal carcinoma. Clin. Cancer Res. 26, 3682\u20133693 (2020).","journal-title":"Clin. Cancer Res."},{"key":"1210_CR37","doi-asserted-by":"publisher","first-page":"e1003535","DOI":"10.1371\/journal.pcbi.1003535","volume":"10","author":"RF Schwarz","year":"2014","unstructured":"Schwarz, R. F. et al. Phylogenetic quantification of intra-tumour heterogeneity. PLoS Comput. Biol. 10, e1003535 (2014).","journal-title":"PLoS Comput. Biol."},{"key":"1210_CR38","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nature17676","volume":"534","author":"S Nik-Zainal","year":"2016","unstructured":"Nik-Zainal, S. et al. Landscape of somatic mutations in 560 breast cancer whole-genome sequences. Nature 534, 47\u201354 (2016).","journal-title":"Nature"},{"key":"1210_CR39","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1038\/nprot.2008.211","volume":"4","author":"W Huang da","year":"2009","unstructured":"Huang da, W., Sherman, B. T. & Lempicki, R. A. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat. Protoc. 4, 44\u201357 (2009).","journal-title":"Nat. Protoc."},{"key":"1210_CR40","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.cell.2018.03.035","volume":"173","author":"F Sanchez-Vega","year":"2018","unstructured":"Sanchez-Vega, F. et al. Oncogenic signaling pathways in the Cancer Genome Atlas. Cell 173, 321\u2013337.e10 (2018).","journal-title":"Cell"},{"key":"1210_CR41","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-015-0700-7","volume":"16","author":"MD Leiserson","year":"2015","unstructured":"Leiserson, M. D., Whu, H. T., Vandin, F. & Raphael, B. J. CoMEt: a statistical approach to identify combinations of mutually exclusive alterations in cancer. Genome Biol. 16, 160 (2015).","journal-title":"Genome Biol."},{"key":"1210_CR42","doi-asserted-by":"publisher","first-page":"1968","DOI":"10.1093\/bioinformatics\/bty920","volume":"35","author":"AA Rizvi","year":"2019","unstructured":"Rizvi, A. A. et al. gwasurvivr: an R package for genome-wide survival analysis. Bioinformatics 35, 1968\u20131970 (2019).","journal-title":"Bioinformatics"}],"container-title":["npj Precision Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41698-025-01210-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41698-025-01210-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41698-025-01210-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T04:39:44Z","timestamp":1767760784000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41698-025-01210-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,5]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1210"],"URL":"https:\/\/doi.org\/10.1038\/s41698-025-01210-2","relation":{},"ISSN":["2397-768X"],"issn-type":[{"value":"2397-768X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,5]]},"assertion":[{"value":"30 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"7"}}